Edgar Filing: Powell Fred M - Form 4

Powell Fred Form 4	М										
June 11, 201											
FORM 4 UNITED STATES SECURITIES AND Washington, D.C.										9PROVAL 3235-0287	
Check th if no long subject to Section 1 Form 4 o Form 5 obligation may cont <i>See</i> Instru 1(b).	GES IN I SECUR 5(a) of the ility Hold	ES IN BENEFICIAL OWNERSHIP OF SECURITIES (a) of the Securities Exchange Act of 1934, ity Holding Company Act of 1935 or Section estment Company Act of 1940					January 31, 2005 Estimated average burden hours per response 0.5				
(Print or Type I	Responses)										
1. Name and Address of Reporting Person <u>*</u> Powell Fred M			2. Issuer Name and Ticker or Trading Symbol ANTARES PHARMA, INC. [ATRS]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	(First) RES PHARMA RINCETON S' JITE 300		3. Date of (Month/D 06/07/20	-	ansaction			Director X Officer (give below)	10%	9 Owner er (specify	
				Amendment, Date Original Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	ecurit	ies Acc	uired, Disposed o	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)				Code	4. Securit on(A) or Dis (D) (Instr. 3, 4	sposed	l of	Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	06/07/2018			Code V F	Amount 9,609 (1)	or (D) D	Price \$ 2.7	Transaction(s) (Instr. 3 and 4) 321,825	D		
Common Stock	06/08/2018			А	91,667 (2)	А	\$ 2.7	413,492	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Powell Fred M - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) of Disposed of (D (Instr. 3, 4, and 5)	Expiration I (Month/Day or	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (E	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 2.7	06/08/2018		А	177,453 (<u>3)</u>	(4)	06/08/2028	Common Stock	177,453	

Reporting Owners

Reporting Owner Name / Address	Relationships					
reporting of the Funct / Functions	Director	Director 10% Owner Officer		Other		
Powell Fred M C/O ANTARES PHARMA, INC. 100 PRINCETON STREET SOUTH, SUITE 300 EWING, NJ 08628			Executive Vice President & CFO			
Signatures						
/s/Keith Muckenhirn as attorney-in-fact for Fred M Powell		06/11/2018				
** Signature of Reporting Person		Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award.
- (2) Represents grant of restricted stock units made under the 2008 Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant.
- (3) Represents grant of options to purchase shares of common stock, par value \$0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan.
- (4) The options vest in equal quarterly installments over three years from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.